spacer
home > epc > Winter 2015
PUBLICATIONS

European Pharmaceutical Contractor

epc
Winter 2015

   
Text
PDF
bullet
Marketplace & Business
CRO Growth

Deal Me In


Contract research continues to thrive as CROs strengthen their R&D services and sponsors tighten their budgets. Growth is surging this year and predicted to at least the end of the decade, driven by the big players and market consolidation. EPC has more.
 
view
download pdf
bullet
Legal & Regulatory
Patent Protection

Optional Extras


It is uncertain times for patent portfolios in Europe, with pharma companies large and small working out whether to opt in or out of the Unifi ed Patent Court system, coming in 2017. The risks, rewards and – crucially – costs of the new regime must all be weighed up, says Paul Harris at Pillsbury Law.
 
view
download pdf
bullet
Science & Innovation
Business Models

Eco Friendly

A new ecosystem model is rapidly evolving in pharma and life sciences. Heather Fraser at IBM explains how it will require a level of collaboration the industry has not engaged in before, transcending boundaries and stimulating a growth in innovation.
 
view
download pdf
bullet
DATA MANAGEMENT
Q&A: Investigator Site Data

Joint Ventures


Through collaborative efforts such as the Shared Investigator Platform, biopharma partners are working to lessen administrative burdens for investigators and enhance the patient experience. Jackie Kent of Eli Lilly and TransCelerate talks to EPC.
 
view
download pdf
bullet
Risk Management
Pharmacovigilance

Progress Report


EPC offers a run-down of specific measures being implemented by the EMA to maximise the efficiency of the EudraVigilance safety reporting system for adverse events, following a significant decline in signals in 2014.
 
view
download pdf

Research and Development
Preclinical Development

Non-Clinics: Progression

Exploring the changing face of non-clinical development, Envigo's Lee Coney looks at the intricacies of investigating the safety and pharmacology of biologic drugs before they enter clinical trials, and the essential role of CRO players.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement